PL3606515T3 - Preparat inhibitora STAT3 - Google Patents

Preparat inhibitora STAT3

Info

Publication number
PL3606515T3
PL3606515T3 PL18720845T PL18720845T PL3606515T3 PL 3606515 T3 PL3606515 T3 PL 3606515T3 PL 18720845 T PL18720845 T PL 18720845T PL 18720845 T PL18720845 T PL 18720845T PL 3606515 T3 PL3606515 T3 PL 3606515T3
Authority
PL
Poland
Prior art keywords
inhibitor formulation
stat3 inhibitor
stat3
formulation
inhibitor
Prior art date
Application number
PL18720845T
Other languages
English (en)
Other versions
PL3606515T4 (pl
Inventor
Robert H. Shoemaker
Jonathan M. WHITE
Shanker Gupta
Original Assignee
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services
Glg Pharma, Llc
Mri Global
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The U.S.A. As Represented By The Secretary, Department Of Health And Human Services, Glg Pharma, Llc, Mri Global filed Critical The U.S.A. As Represented By The Secretary, Department Of Health And Human Services
Publication of PL3606515T4 publication Critical patent/PL3606515T4/pl
Publication of PL3606515T3 publication Critical patent/PL3606515T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63Esters of sulfonic acids
    • C07C309/72Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL18720845T 2017-04-05 2018-04-05 Preparat inhibitora STAT3 PL3606515T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762481960P 2017-04-05 2017-04-05
PCT/US2018/026228 WO2018187551A1 (en) 2017-04-05 2018-04-05 Stat3 inhibitor formulation
EP18720845.9A EP3606515B1 (en) 2017-04-05 2018-04-05 Stat3 inhibitor formulation

Publications (2)

Publication Number Publication Date
PL3606515T4 PL3606515T4 (pl) 2022-02-14
PL3606515T3 true PL3606515T3 (pl) 2022-02-14

Family

ID=62067809

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18720845T PL3606515T3 (pl) 2017-04-05 2018-04-05 Preparat inhibitora STAT3

Country Status (15)

Country Link
US (1) US10913709B2 (pl)
EP (1) EP3606515B1 (pl)
JP (1) JP2020513022A (pl)
KR (1) KR20200043930A (pl)
CN (1) CN110944631A (pl)
AU (1) AU2018248303A1 (pl)
BR (1) BR112019020985A2 (pl)
CA (1) CA3058973A1 (pl)
CL (1) CL2019002843A1 (pl)
CO (1) CO2019012386A2 (pl)
ES (1) ES2888235T3 (pl)
MX (1) MX2019011913A (pl)
PE (1) PE20200611A1 (pl)
PL (1) PL3606515T3 (pl)
WO (1) WO2018187551A1 (pl)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191285B1 (en) 1997-07-03 2001-02-20 Abbott Laboratories Process for the preparation of ketorolac tromethamine
WO2007136858A2 (en) * 2006-05-19 2007-11-29 H. Lee Moffitt Cancer Center & Research Institute Small molecule inhibitors of stat3 with anti-tumor activity
WO2010062681A2 (en) 2008-10-30 2010-06-03 University Of South Florida Luteolin and diosmin/diosmetin as novel stat3 inhibitors for treating autism
EP2370082A4 (en) * 2008-12-01 2012-05-30 Univ Central Florida Res Found FOR BELLY CANCER CELLS CYTOTOXIC DRUG COMPOSITION
WO2012159107A1 (en) 2011-05-19 2012-11-22 Rhode Island Hospital Inhibition of renal fibrosis
TWI670080B (zh) * 2014-10-08 2019-09-01 國立陽明大學 抑制癌細胞及/或癌症幹細胞之存活、癌化及轉移之方法

Also Published As

Publication number Publication date
AU2018248303A1 (en) 2019-11-07
PL3606515T4 (pl) 2022-02-14
ES2888235T3 (es) 2022-01-03
BR112019020985A2 (pt) 2020-05-05
EP3606515B1 (en) 2021-06-02
WO2018187551A1 (en) 2018-10-11
CL2019002843A1 (es) 2020-06-12
MX2019011913A (es) 2021-09-24
US10913709B2 (en) 2021-02-09
KR20200043930A (ko) 2020-04-28
JP2020513022A (ja) 2020-04-30
PE20200611A1 (es) 2020-03-10
US20200109109A1 (en) 2020-04-09
CN110944631A (zh) 2020-03-31
CO2019012386A2 (es) 2020-01-31
EP3606515A1 (en) 2020-02-12
CA3058973A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
IL283639A (en) kif18a inhibitors
IL269196A (en) New inhibitors
GB201705971D0 (en) Inhibitor compounds
SG11202010347XA (en) Stat3 inhibitors
IL274139A (en) Sprayable formulation
IL265139B (en) Dopamine-b-hydroxylase inhibitors
ZA201907136B (en) Ip6k inhibitors
GB201612860D0 (en) Inhibitors
IL276013A (en) pi4kiiibeta inhibitors
IL274719A (en) formulation
GB201713724D0 (en) Formulation
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors
IL274550A (en) Dopamine-B-hydroxylase inhibitors
GB201706969D0 (en) Formulation
SG11202102727RA (en) Immunoproteasome inhibitor formulation
GB201719464D0 (en) Formulation
PL3606515T3 (pl) Preparat inhibitora STAT3
GB201721465D0 (en) Inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors
GB2568045B (en) Formulation
GB201812462D0 (en) Inhibitors
GB201720145D0 (en) Inhibitor compounds
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors
GB201720808D0 (en) Formulation
GB201708510D0 (en) Inhibitor compounds